DadFinStart your free week
DadFin › Stocks › Healthcare › TKNO

Alpha Teknova, Inc. (TKNO) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$8.84 ▲ +4.74% today

80.7
Dad Score, out of 100
good

Alpha Teknova, Inc. (TKNO) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 80.7 out of 100 on the Dad Score, a good reading that places the business ahead of 81% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #171 of 974. Its strongest axes are valuation, quality and growth; its weakest are risk and conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Above average
Growth
Above average
Price action
Above average
Risk
Weak
Conviction
Below average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-47.3×
Dividend yield0.00%
Return on capital-17.2%
Operating margin-23.7%
Revenue growth (YoY)+7.3%
FCF yield-2.0%
Net debt / EBITDA3.00×
Piotroski F-Score5 / 9
52-week change+59.1%
Market cap$483M
Next earningsNov 5, 2026

What subscribers see on TKNO

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.